CAREER PRESS CENTER DRUGS OUR ACTIVITY INNOVATION ABOUT GLENMARK HOME Drug development ABOUT GLENMARK Overview Our vision and values Areas of activity Drug development Finished medicines Glenmark Generics Ltd (GGL) History Progress Glenmark in the World Eco concept Contacts DRUG DEVELOPMENT Glenmark's drug innovation activities primarily focus on therapeutic areas such as inflammatory diseases [asthma / COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, etc.] and pain relief [neuropathic pain and pain of inflammatory etiology]. Glenmark is actively developing 13 molecules that are currently at various stages of preclinical and clinical development. 8 of these molecules are in clinical trials. All of these molecules are advanced treatments for serious chronic disease and are potential blockbusters. The potential sales of each of the new molecules could range from US $ 1 billion to US $ 3 billion. At the same time, Glenmark is actively pursuing a strategy of selling licenses for its molecules, which are in clinical development, to large international pharmaceutical companies. Based on the results to date, the licensing strategy has proven to be very successful. Over the past 5 years, the company has concluded 4 transactions, which made it possible to receive USD 115 million in advance and milestone payments. This business is distributed among 3 specialized research centers. New Chemical Compounds (NCC) research is being conducted at a state-of-the-art facility in Navi Mumbai, India. Over 200 scientists work at this research center. It is a complete, holistic organization with experts in all areas of the development and development of NHCs (new chemical compounds), from goal definition to clinical development. Glenmark biopharmaceutical research is carried out at a research center in Switzerland. This center specializes in the discovery and development of new monoclonal antibodies (MAT). A research center in Switzerland has the capacity to develop MAT from the moment of receipt to preclinical and clinical research. In addition, Glenmark has invested heavily in another state-of-the-art R&D facility in Oxford, UK for molecules undergoing clinical trials. This R&D center plays the role of a global Glenmark center for clinical development and research, both new chemical compounds and biotech drugs. More details Home  •  About Glenmark  •  Innovation  •  Our Business  •  News  •  Career  •  Contact All rights reserved © Glenmark, 2010 - 2018